Last checked at 
LONDON (Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:----------FTSE 100----------LIBERUM RAISES FERGUSON PRICE TARGET TO 6175 (5800) PENCE - 'BUY'----------DEUTSCHE BANK RAISES SSE TARGET TO 1200 (1150) P - 'SELL'----------JPMORGAN REINITIATES GLAXOSMITHKLINE WITH 'NEUTRAL' - PRICE TARGET 1500 PENCE----------GOLDMAN RAISES RBS PRICE TARGET TO 335 (310) PENCE - 'NEUTRAL'----------CREDIT SUISSE RAISES MEDICLINIC INTERNATIONAL TARGET TO 660 (630) PENCE - 'NEUTRAL'----------JPMORGAN RAISES NATIONAL GRID PRICE TARGET TO 950 (870) PENCE - 'OVERWEIGHT'----------FTSE 250----------JPMORGAN RESUMES FIRSTGROUP WITH 'OVERWEIGHT' - TARGET 133 PENCE----------BERENBERG RAISES BRITVIC TO 'BUY' ('HOLD') - TARGET 900 (725) PENCE----------GOLDMAN CUTS VEDANTA RESOURCES PRICE TARGET TO 775 (800) PENCE - 'NEUTRAL'----------JPMORGAN RAISES OCADO PRICE TARGET TO 871 (505) PENCE - 'NEUTRAL'----------UBS RAISES ELECTROCOMPONENTS PRICE TARGET TO 745 (680) PENCE - 'NEUTRAL'----------HSBC RAISES B&M PRICE TARGET TO 500 (470) PENCE - 'BUY'----------UBS CUTS PARAGON BANKING GROUP PRICE TARGET TO 525 (530) PENCE - 'BUY'----------UBS RAISES OCADO TO 'NEUTRAL' ('SELL') - TARGET 750 (280) PENCE----------OTHER MAIN MARKET AND AIM----------KEPLER CHEUVREUX CUTS PHOTO-ME PRICE TARGET TO 153 (200) PENCE - 'BUY'----------LIBERUM RAISES GRESHAM HOUSE PRICE TARGET TO 638 PENCE - 'BUY'----------CREDIT SUISSE CUTS OPHIR ENERGY TO 'NEUTRAL' ('OUTPERFORM') - TARGET 60 (80) PENCE----------
30 Jun 2023 22:38
First trial over Zantac cancer claims set for November
June 30 (Reuters) - The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state court on Nov. 13, a lawyer for plaintiffs in the litigation said Friday.
Read more